Carbapenem Based Antibiotics Market Analysis, Region & Country Revenue Share, & Forecast Till 2028

The Carbapenem Based Antibiotics Market size is projected to reach US$ 5,346.62 million by 2028 from US$ 3,964.57 million in 2021; it is estimated to grow at a CAGR of 4.4% from 2021 to 2028.

Generic versions of antibiotics are popular due to their availability and affordability. In addition, the expiry of patented carbapenem-based antibiotics has widen-up opportunities for generic drug manufacturers to enter the market with their cost-efficient drugs. The focus of generic drug producers is to increase the reach of these drugs. Moreover, the shortage of antibiotics to treat bacterial infections is also one of the prime factors driving the market's growth. The increased production of generic carbapenem-based antibiotics has enlarged the drug availability in various low- and middle-income countries.

Get a Sample PDF of report at- https://www.premiummarketinsights.com/sample/TIP00073365?utm_source=OpenPr&utm_medium=10640

The List of Companies -
1. Pfizer Inc.
2. Savior Lifetec
3. Sumitomo Dainippon Pharma Co., Ltd.
4. Merck & Co., Inc.
5. Gland Pharma Limited
6. Aurobindo Pharma Ltd
7. Daewoong Pharmaceutical Co.,Ltd,
8. Iterum Therapeutics plc
9. ACS Dobfar S.p.A
10. Spero Therapeutics

Based on geography, the carbapenem-based antibiotics market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America. North America dominates the global market share and is expected to hold its strong foothold in the coming years. The region is expected to witness a consistent growth in the future owing to factors such as increased adoption of carbapenem based antibiotics, high prescription rate of antibiotics, and advancements in research and development leading to the emergence and launch of new medicines.

However, the market in Asia Pacific is expected to witness the fastest growth in the coming years. The carbapenem-based antibiotics market size in India and China is expected to grow rapidly owing to factors such as the large population, increasing focus of market players on developing novel vaccines and products at affordable prices, and high penetration of market players manufacturing generic drugs and exporting them across the world.

Get Full Report: https://www.premiummarketinsights.com/reports-tip/carbapenem-based-antibiotics-market

Generic versions of carbapenem drugs available in the market are ertapenem (Invanz), imipenem/cilastatin (Primaxin IM), doripenem (Doribax), and meropenem (Merrem). In addition, the growing number of generic players in the market is accelerating the production of generic drugs. Many Asian companies are engaged in developing active pharmaceutical ingredients (API), which are required to produce generic carbapenem-based antibiotics. In June 2021, JW Pharmaceutical, a South Korean company, announced it had completed production of its API for Ertapenem injection and shipped it to the US.

The company plans to enter the global carbapenem antibiotic market in the coming years. It has also succeeded in developing its technology independently in Korea to produce Doripenem. Furthermore, the company plans to expand the sales of both API and finished drugs of Imipenem and Meropenem by exporting them to over 40 countries, including China and Japan. As a result, companies are accelerating generic drug production and driving the growth of the global carbapenem-based antibiotics market.

Buy a copy of this research report at @: https://www.premiummarketinsights.com/buy/TIP00073365?utm_source=OpenPr&utm_medium=10640

TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 By Type
1.3.2 By Indication
1.3.3 By Distribution Channel
1.3.4 By Geography
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America- PEST Analysis
4.2.2 Europe- PEST Analysis
4.2.3 Asia Pacific- PEST Analysis
4.2.4 Middle East and Africa- PEST Analysis
4.2.5 South and Central America- PEST Analysis
4.3 Expert Opinions
5. Key Market Dynamics
5.1 Drivers
5.1.1 Rising Prevalence of Gram-Negative Bacterial Infections
5.1.2 Increasing Production of Generic Drugs
5.2 Market Restraints
5.2.1 Tedious and Expensive Process of Antibiotic Development
5.3 Market Opportunities
5.3.1 Private and Public Partnerships
5.4 Future Trends
5.4.1 Strategic Advancement for New Antibiotic Identification
5.5 Impact Analysis
6. Global Analysis
7. By Type
8. By Indication
Continued…

Contact Us:
If you have any queries about this report or if you would like further information, please
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email: sales@premiummarketinsights.com

About Us:
Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost-effective research reports and solutions from various publishers.
The market research industry has changed in last decade. As corporate focus has shifted to niche markets and emerging countries, a number of publishers have stepped in to fulfil these information needs. We have experienced and trained staff that helps you navigate different options and lets you choose best research solution at most effective cost.
Premium Market Insights has an extensive coverage of industry reports, company reports and country reports across all industries. In case your research needs are not met by syndicated reports offered by leading publishers, we can help you by offering a customized research solution by liaising with different research agencies saving your valuable time and money.
We provide best in class customer service and our customer support team is always available to help you on your research queries. Our commitment to customer service is best exemplified by free analyst support that we offer to our clients which sets us apart from any other provider. We also offer enterprise subscriptions which provide significant cost savings to our clients.

This release was published on openPR.